Quantcast

Latest Novo Nordisk Inc. Stories

2014-09-11 20:21:50

WASHINGTON, Sept. 11, 2014 /PRNewswire/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda(®), the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity. Based on the data contained in the NDA for Saxenda(®), the FDA asked the panel members to discuss whether...

2014-08-28 08:28:11

PLAINSBORO, N.J., Aug. 28, 2014 /PRNewswire/ -- Results from an analysis of US respondents from Novo Nordisk's Diabetes Attitudes, Wishes and Needs 2 (DAWN2(TM)) study were published recently in Current Medical Research and Opinion. The study shows that minority populations in the US with diabetes, including African Americans, Chinese Americans, and Hispanics, reported positive psychological well-being, better quality of life, and feeling more empowered with respect to their diabetes...

2014-06-19 08:30:01

Latest delivery device advancement in the basal insulin category PLAINSBORO, N.J., June 19, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest prefilled insulin delivery device Levemir(®) FlexTouch(®) (insulin detemir [rDNA origin] injection) in the United States. This device represents an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-06 08:25:22

Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation and leadership in diabetes care, will be presented today with a 2014 New Good Neighbor Award for its new LEED Silver certified US headquarters in Plainsboro, New Jersey. The company was given this award based on a variety of factors, including economic benefit/job creation, architectural merit, and...

2014-05-16 08:25:50

LAS VEGAS, May 16, 2014 /PRNewswire/ -- Results from the SCALE(TM) Obesity and Pre-diabetes phase 3a trial will be presented on May 16, 2014, for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists (AACE). Data showed that after 56 weeks of treatment, liraglutide 3 mg, in combination with diet and exercise, provided significantly greater weight loss of 8% from baseline compared to 2.6% with placebo (P<0.0001). This is the largest...

2014-01-30 12:28:13

PRINCETON, N.J., Jan. 30, 2014 /PRNewswire/ -- Novo Nordisk (NYSE: NVO), a global healthcare company with 90 years of innovation and leadership in diabetes care, announced the promotion of Eddie Williams to senior vice president of biopharmaceuticals, effective February 1, 2014. (Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO) "Our biopharmaceutical business will be increasingly important to our growth in the U.S. as we apply the protein expertise developed through...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'